

# TRIM33 Antibody (C-term) Blocking peptide

Synthetic peptide Catalog # BP13643b

# **Specification**

### TRIM33 Antibody (C-term) Blocking peptide - Product Information

**Primary Accession** 

**Q9UPN9** 

# TRIM33 Antibody (C-term) Blocking peptide - Additional Information

**Gene ID** 51592

#### **Other Names**

E3 ubiquitin-protein ligase TRIM33, 632-, Ectodermin homolog, RET-fused gene 7 protein, Protein Rfg7, Transcription intermediary factor 1-gamma, TIF1-gamma, Tripartite motif-containing protein 33, TRIM33, KIAA1113, RFG7, TIF1G

### Target/Specificity

The synthetic peptide sequence used to generate the antibody AP13643b was selected from the C-term region of TRIM33. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

### **Format**

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

#### Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

#### **Precautions**

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

### TRIM33 Antibody (C-term) Blocking peptide - Protein Information

### Name TRIM33

Synonyms KIAA1113, RFG7, TIF1G

### **Function**

Acts as an E3 ubiquitin-protein ligase. Promotes SMAD4 ubiquitination, nuclear exclusion and degradation via the ubiquitin proteasome pathway. According to PubMed:<a href="http://www.uniprot.org/citations/16751102" target="\_blank">16751102</a>, does not promote a decrease in the level of endogenous SMAD4. May act as a transcriptional repressor. Inhibits the transcriptional response to TGF-beta/BMP signaling cascade. Plays a role in the control of cell proliferation. Its association with SMAD2 and SMAD3 stimulates erythroid differentiation of hematopoietic stem/progenitor (By similarity). Monoubiquitinates SMAD4 and acts as an inhibitor of SMAD4-dependent TGF-beta/BMP signaling cascade (Monoubiquitination of SMAD4 hampers its ability to form a stable complex with activated SMAD2/3 resulting in inhibition of TGF-beta/BMP



signaling cascade).

#### **Cellular Location**

Nucleus. Note=In discrete nuclear dots resembling nuclear bodies (By similarity). Localizes to sites of DNA damage (PubMed:25593309). {ECO:0000250|UniProtKB:Q99PP7, ECO:0000269|PubMed:25593309}

#### **Tissue Location**

Expressed in stem cells at the bottom of the crypts of the colon (at protein level). Expressed in colon adenomas and adenocarcinomas (at protein level). Expressed in brain, lung, liver, spleen, thymus, prostate, kidney, testis, heart, placenta, pancreas, small intestine, ovary, colon, skeletal muscle and hematopoietic progenitors

# TRIM33 Antibody (C-term) Blocking peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

### Blocking Peptides

TRIM33 Antibody (C-term) Blocking peptide - Images

# TRIM33 Antibody (C-term) Blocking peptide - Background

The protein encoded by this gene is thought to be atranscriptional corepressor. However, molecules that interact withthis protein have not yet been identified. The protein is a member of the tripartite motif family. This motif includes threezinc-binding domains, a RING, a B-box type 1 and a B-box type 2, and a coiled-coil region. Three alternatively spliced transcriptvariants for this gene have been described, however, thefull-length nature of one variant has not been determined.

# TRIM33 Antibody (C-term) Blocking peptide - References

Bai, X., et al. Cell 142(1):133-143(2010)Howard, P.W., et al. Biochem. Biophys. Res. Commun. 396(3):674-678(2010)Vincent, D.F., et al. PLoS Genet. 5 (7), E1000575 (2009) :Dupont, S., et al. Cell 136(1):123-135(2009)Sugiyama, N., et al. Mol. Cell Proteomics 6(6):1103-1109(2007)